Saint Petersburg

The trials here

What the 6 trials at this site are about, from their registry records.

Conditions

• Childhood cancers2 trials
• Lung cancer2 trials
• Bladder cancer1 trial
• Chronic myeloid leukaemia1 trial
• Melanoma1 trial
• Psoriasis1 trial
• Psoriatic arthritis1 trial

Phase

• Phase 34 trials
• Phase 22 trials

Status

• Completed3 trials
• Active, not recruiting2 trials
• Withdrawn1 trial

Lead sponsor

• Bristol-Myers Squibb6 trials

Running trials

• Active, not recruiting

  A Study to Determine the Efficacy and Safety of Deucravacitinib Compared With Placebo in Participants With Active Psoriatic Arthritis (PsA) Who Are Naïve to Biologic Disease-modifying Anti-rheumatic Drugs

  NCT04908202· Phase 3· Bristol-Myers Squibb· Source

• Active, not recruiting

  A Study of Neoadjuvant Chemotherapy Plus Nivolumab Versus Neoadjuvant Chemotherapy Plus Placebo, Followed by Surgical Removal and Adjuvant Treatment With Nivolumab or Placebo for Participants With Surgically Removable Early Stage Non-small Cell Lung Cancer

  NCT04025879· Phase 3· Bristol-Myers Squibb· Source

Closed trials

• Withdrawn

  Neoadjuvant Nivolumab+Ipilimumab Followed by Adjuvant Nivolumab or Neoadjuvant Nivolumab+Ipilimumab Followed by Adjuvant Observation Compared With Adjuvant Nivolumab in Treatment-Naive High-risk Melanoma Participants

  NCT04495010· Phase 2· Bristol-Myers Squibb· Source

• Completed

  A Study of Nivolumab and Ipilimumab in Untreated Participants With Stage 3 Non-small Cell Lung Cancer (NSCLC) That is Unable or Not Planned to be Removed by Surgery

  NCT04026412· Phase 3· Bristol-Myers Squibb· Source

• Completed

  A Study to Compare Chemotherapy Alone Versus Chemotherapy Plus Nivolumab or Nivolumab and BMS-986205, Followed by Continued Therapy After Surgery With Nivolumab or Nivolumab and BMS-986205 in Participants With Muscle Invasive Bladder Cancer

  NCT03661320· Phase 3· Bristol-Myers Squibb· Source

• Completed

  A Phase II Study of Dasatinib in Children and Adolescents With Newly Diagnosed Chronic Phase Chronic Myelogenous Leukemia (CML) or With Ph+ Leukemias Resistant or Intolerant to Imatinib

  NCT00777036· Phase 2· Bristol-Myers Squibb· Source